比较基因组杂交新进展--Array-based CGH

比较基因组杂交(CGH)目前已在肿瘤的遗传学研究中得到广泛应用,但其技术上存在的一些缺陷明显制约了它的发展;Arraybased CGH是一项建立在芯片技术基础之上的新的CGH方法,其自动化、高通量、高敏感性的特点很大程度上弥补了传统CGH方法的不足.     

应用微阵列比较基因组杂交技术精确诊断不平衡染色体畸变

目的 探讨微阵列比较基因组杂交技术(array-based comparative genomic hybridization,array-CGH)在诊断不平衡染色体畸变中的应用价值.方法 选取4例常规G显带染色体核型分析未能确诊的不平衡染色体畸变病例,按照标准的Affymetrix SNP 6.0微阵列的操作手册进行杂交、洗涤及全基因组扫描,并通过相应的计算机软件分析结果.结果 通过array-CGH技术分析,明确了所有4例染色体不平衡畸变的诊断并且进行精确定位,其中对2例患者镜下染色体出现无法确定来源的额外条带进行了自身直接重复的确诊;对2例患者G显带无法识别的缺失合并重复的衍生染色体进行了精确诊断.结论 array-CGH技术在DNA水平上对染色体不平衡畸变的诊断具有独特的高分辨率、高敏感性和高特异性,并且能够精确定位,对染色体疾病作出基因型-表型关系的诊断具有重大的应用价值.     

微阵列比较基因组杂交分析一例足月小样儿的染色体畸变

目的 分析一例足月小样儿的染色体畸变,探讨患儿低出生体重的原因.方法 采集临床已确诊的足月小样儿外周血并抽提基因组DNA,进行微阵列比较基因组杂交,分析患儿基因组拷贝数的改变.培养患儿及其父母外周血淋巴细胞,进行染色体核型分析并确定患儿染色体畸变的来源.结果 微阵列比较基因组杂交显示患儿在10q125.2→qter区域存在长22 Mb片段的重复,同时在15q26.2→qter区域存在长5 Mb片段的缺失.核型分析显示患儿核型为46,XY,-15,+der(15)t(10;15)(q25;q26)pat.结论 患儿在10q25.2→qter区域存在部分三体,而在15q26.2→qter区域存在部分单体,这两种染色体畸变可能均是导致患儿表现为足月小样儿的病因之一.     

比较基因组杂交技术的应用

肿瘤发生和发育畸形与染色体的不平衡有关,包括染色体的扩增和缺失.常规的比较基因组杂交技术(conventional comparative genomic hybridization)由于能在一次试验中掌握整个基因组DNA拷贝数的变化并可以将此改变准确的定位于染色体,因而在探讨肿瘤的发生和生长发育畸形机理的研究方面得到了广泛的应用.在此基础上发展起来的微阵列比较基因组杂交技术(microarray CGH/ array-based CGH),为精确、定量地研究人类基因组微缺失和微扩增及其定位提供了有力工具.本文综述了CGH和CGHa 技术的原理及应用.     

微阵列——比较基因组杂交技术及其应用

微阵列一比较基因组杂交技术是一种集基因芯片和传统比较基因组杂交为一体的新技术。近年来，该技术已成为遗传学家探索生命科学，特别是肿瘤和遗传性疾病基因和染色体异常的有力工具。本文就微阵列一比较基因组杂交技术的特点、分类和实际应用以及未来的应用前景作一简要介绍。     

应用比较基因组杂交技术进行畸形胎儿的染色体核型分析

目的应用比较基因组杂交（Comparative Genomic Hybridization,CGH）方法,快速进行畸形胎儿的染色体核型分析。方法选取畸形胎儿标本11例,采用Tiangen DNA抽提试剂盒提取羊水或脐血基因组DNA,Vysis缺口平移试剂盒标记待测DNA和对照DNA,同时将待测DNA和对照DNA的荧光颜色互换,即进行荧光互换CGH,最后根据绿红两种信号的比值制作CGH拷贝数核型模式图。结果11例畸形胎儿的样本均成功的利用荧光互换CGH方法进行了分析、确认,平均用时3.5天。其中1例CGH核型为Dup21,1例CGH核型为Del2p24-pter,Dup12p13,1例CGH核型为Del1p33-pter,Del22q11-12。结论荧光互换CGH方法快速进行畸形胎儿染色体的核型分析具有可行性。     

微阵列--比较基因组杂交技术及其应用

微阵列-比较基因组杂交技术是一种集基因芯片和传统比较基因组杂交为一体的新技术.近年来,该技术已成为遗传学家探索生命科学,特别是肿瘤和遗传性疾病基因和染色体异常的有力工具.本文就微阵列-比较基因组杂交技术的特点、分类和实际应用以及未来的应用前景作一简要介绍.     

荧光原位杂交联合微阵列比较基因组杂交分析一例原发性闭经患者的染色体畸变

目的分析1例原发性闭经患者的染色体畸变,探讨该患者原发性闭经的可能原因。方法采集临床已确诊的原发性闭经患者外周血,并抽提基因组DNA,进行荧光原位杂交和微阵列比较基因组杂交,分析染色体异常。结果微阵列比较基因组杂交显示患者染色体Xp22.31区域存在长1.637Mb片段的三倍体,Xp21.2-q21.1区域存在长52.156 Mb片段的重复片段。结论微阵列比较基因组杂交技术可以检测染色体微小畸变,值得临床推广应用。     

利用比较基因组杂交技术分析食管癌组织中染色体基因组的变化特征

目的　探讨河南食管癌高发区居民食管癌发生发展的基因组变化特征。方法　应用比较基因组杂交技术分析52例原发性食管癌患者染色体基因组变化,按临床分期、有无淋巴结及远处转移进行分组比较。结果　在食管癌中3q、8q、5p、1q、6q、18p、20q的染色体基因组扩增和3p、1p、9q、19p、4p、8p染色体基因组丢失频繁( >20% )。3q、5p、1q、11q13 14的染色体基因组扩增和4pq、13q染色体基因组丢失与食管癌病理分期相关(P<0 .05)。8q扩增和4p丢失与淋巴结转移相关(P<0. 05)。2p扩增和4pq、l1q14 qter的丢失与远处器官转移相关(P<0 .05)。结论　染色体3q、8q、5p、1q、6q、18p和20q部位可能存在与食管癌变密切相关的癌基因, 3p、1p、9q、19p、4p和8p可能存在与食管癌变密切相关的抑癌基因; 3q、5p、1q、11q13 14扩增和4pq、13q丢失与食管癌的发展相关,而8q、2p扩增和4pq、11q14 qter的丢失是食管癌发展的晚期事件与食管癌转移相关,不同的基因参与了淋巴结转移和远处器官转移。     

微阵列比较基因组杂交技术对一例胎儿染色体复杂易位的产前诊断

目的对1例5条染色体发生复杂易位的胎儿作出产前诊断,评价微阵列比较基因组杂交（array—CGH）技术在产前诊断中的应用价值。方法应用G显带分析羊水细胞染色体及夫妇双方外周血染色体,应用array—CGH技术对羊水细胞进行全基因组高分辨扫描分析,了解是否有微小缺失和重复。结果羊水细胞染色体结果为46,XX,t（5;7;12）,t（14;21）,夫妻双方外周血染色体核型正常,羊水细胞array—CGH结果显示胎儿染色体未发生微缺失或微重复。结论array—CGH技术与传统细胞学技术相结合,大大提升产前诊断技术水平。     

Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation

Renal cell carcinomas (RCCs) with sarcomatoid transformation show the most malignant behaviour of all renal carcinoma types. In this study, comparative genomic hybridization was used to screen for losses and gains of DNA sequences along all chromosome arms in 12 sarcomatoid (S) RCCs. On average, there were 8·6 aberrations per tumour. DNA sequence losses (5·2±4·4) were slightly more frequent than gains (3·4±2·6). DNA gains most often involved chromosomes 17 (33 per cent), 7, and 8q (25 per cent each). High-level co-amplification involving 11q22–23 and 7p21–22 in one SRCC was not present in adjacent non-sarcomatous tumour areas, raising the possibility of oncogene involvement at these loci for sarcomatoid transformation. DNA losses were most prevalent at 13q (75 per cent) and 4q (50 per cent), suggesting that inactivation of tumour suppressor genes at chromosomes 13q and 4q may be linked to sarcomatoid growth of RCC. It is concluded that SRCCs are genetically highly complex. Chromosomes 13q, 4q, 7p21–22, and 11q22–23 may carry genes with relevance for sarcomatoid growth in RCC. © 1998 John Wiley & Sons, Ltd.     

鼻咽癌的比较基因组杂交研究

目的：研究鼻咽癌的遗传变异特性。方法：采用激光微切割技术分离鼻咽癌细胞DNA，用比较基因组杂交检测6例鼻咽癌组织。结果：6q12-22、8q染色体区域的扩增，染色体11q23-24、13q基因缺失。结论：鼻咽癌具有染色体变异，其中6q12-22、8q、11q23-24和13q区域可能存在一些与鼻咽癌相关的未知基因。     

Unclassified renal cell carcinoma: a clinicopathological,comparative genomic hybridization,and whole-genome exon sequencing study

Unclassified renal cell carcinoma (URCC) is a rare variant of RCC, accounting for only 3-5% of all cases. Studies on the molecular genetics of URCC are limited, and hence, we report on 2 cases of URCC analyzed using comparative genome hybridization (CGH) and the genome-wide human exon GeneChip technique to identify the genomic alterations of URCC. Both URCC patients (mean age, 72 years) presented at an advanced stage and died within 30 months post-surgery. Histologically, the URCCs were composed of undifferentiated, multinucleated, giant cells with eosinophilic cytoplasm. Immunostaining revealed that both URCC cases had strong p53 protein expression and partial expression of cluster of differentiation-10 and cytokeratin. The CGH profiles showed chromosomal imbalances in both URCC cases: gains were observed in chromosomes 1p11-12, 1q12-13, 2q20-23, 3q22-23, 8p12, and 16q11-15, whereas losses were detected on chromosomes 1q22-23, 3p12-22, 5p30-ter, 6p, 11q, 16q18-22, 17p12-14, and 20p. Compared with 18 normal renal tissues, 40 mutated genes were detected in the URCC tissues, including 32 missense and 8 silent mutations. Functional enrichment analysis revealed that the missense mutation genes were involved in 11 different biological processes and pathways, including cell cycle regulation, lipid localization and transport, neuropeptide signaling, organic ether metabolism, and ATP-binding cassette transporter signaling. Our findings indicate that URCC may be a highly aggressive cancer, and the genetic alterations identified herein may provide clues regarding the tumorigenesis of URCC and serve as a basis for the development of targeted therapies against URCC in the future.     

比较基因组杂交研究鼻咽癌遗传变异

目的 了解鼻咽癌遗传学改变的特征。方法 应用比较基因组杂交检测20例鼻咽癌基因组的不平衡即DNA的丢失或扩增。结果 鼻咽癌常见的扩增的染色体是1q、2、3q、7q、8q、12;常见的缺失的染色体为3p、9p、11q、16q。结论 鼻咽癌细胞中存在多条染色体拷贝数的改变,由此引起相应瘤基因的扩增和抑癌基因的丢失可能参与了鼻咽癌的发生、发展。     

Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization

Sporadic renal cell carcinomas (RCCs) display different chromosomal abnormalities according to their morphology; gains of chromosomes 7 and 17 and loss of Y are commonly observed in papillary lesions, whereas loss of 3p sequences and multiple losses of specific chromosomes are found in non-papillary and chromophobe cell carcinomas, respectively. Acquired renal cystic disease (ARCD) is associated with an increased incidence of renal cell tumours, especially papillary lesions. The aim of this study was to examine a series of ARCD-related tumours for chromosomal abnormalities and to compare the findings with those abnormalities commonly observed in sporadic RCCs. Nine tumours from four patients with ARCD were examined using comparative genomic hybridization (CGH) and interphase cytogenetics. Gain of chromosomes 7 and 17 was observed in all four papillary lesions and loss of Y in three. In addition, gain of chromosome 16 was observed in three papillary tumours. Three chromophobe RCCs originating from the same kidney showed different genomic profiles; two had no abnormalities, whereas one showed loss of chromosome 17p. Two non-papillary RCCs failed to show chromosome 3p alterations. In conclusion, renal cell tumours developing in ARCD may show chromosomal abnormalities both similar to and different from those seen in sporadic tumours. Copyright © 1999 John Wiley & Sons, Ltd.     

Array—CGH技术用于产前诊断可疑胎儿染色体异常

目的探讨微阵列比较基因组杂交技术（array—based comparative genomic hybridization,array—CGH）在产前诊断胎儿染色体异常中的应用价值。方法产前诊断发现4例常规G显带染色体核型分析不能明确的胎儿染色体异常,按照标准的array—CGH操作分析对这些病例进行全基因组检测。结果通过array—CGH技术分析,明确了4例胎儿可疑染色体异常的诊断并且进行精确定位,1例染色体部分缺失,1例正常,1例染色体部分重复,1例不平衡易位。结论array—CGH技术对产前诊断胎儿染色体异常具有高分辨率,能够精确定位异常片段,明确胎儿预后,对产前诊断具有重要应用价值。     

Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization

Renal cell carcinoma (RCC) accounts for approximately 3% of all new cancer cases. Although the classification of RCC is based mainly on histology, this method is not always accurate. We applied comparative genomic hybridization (CGH) to determine genomic alterations in 46 cases of different RCC histological subtypes [10 cases of clear cell RCC (CCRCC), 13 cases of papillary RCC (PRCC), 12 cases of chromophobe RCC (CRCC), 9 cases of Xp11.2 translocation RCC (Xp11.2RCC), 2 cases of undifferentiated RCC (unRCC)], and investigated the relationships between clinical parameters and genomic aberrations. Changes involving one or more regions of the genome were seen in all RCC patients; DNA sequence gains were most frequently (>30%) seen in chromosomes 7q, 16p, and 20q; losses from 1p, 3p, 13q, 14q, and 8p. We conclude CGH is a useful complementary method for differential diagnosis of RCC. Loss of 3p21-25, 15q, and gain of 16p11-13 are relatively particular to CCRCC vs. other types of RCC. Gain of 7p13-22, 8q21-24, and loss of 18q12-ter, 14q13-24, and Xp11-q13/Y are more apparent in PRCC, and gain of 8q21-24 is characteristic of type 2 PRCC vs. type 1 PRCC. Loss of 2q12-32, 10p12-15, and 11p11-15, 13p are characteristic of CRCC, and gain of 3p and loss of 11p11-15 and 13p are significant differentiators between common CRCC and CRCC accompanied by sarcomatous change groups. Gain of Xp11-12 is characteristic of the Xp11.2RCC group. Based on Multivariate Cox regression analysis, aberration in 5 chromosome regions were poor prognostic markers of RCC, and include the gain of chromosome 12p12-ter (P = 0.034, RR = 3.502, 95% CI 1.097-11.182), 12q14-ter (P = 0.002, RR = 5.115, 95% CI 1.847-14.170), 16q21-24 (P = 0.044, RR = 2.629, 95% CI 1.027-6.731), 17p12-ter (P = 0.017, RR = 3.643, 95% CI 1.262-10.512) and the loss of 18q12-23 (P = 0.049, RR = 2.911, 95% CI 1.006-8.425), which may provide clues of new genes involved in RCC tumorigenesis.